Immediate Impact
1 from Science/Nature 43 standout
Citing Papers
Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
2025 Standout
Digestive cancers: mechanisms, therapeutics and management
2025 Standout
Works of Akihiro Ohba being referenced
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial
2024
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).
2022
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Akihiro Ohba | 242 | 224 | 168 | 50 | 383 | |
| Jyotsna Fuloria | 165 | 143 | 122 | 30 | 345 | |
| Fei Liu | 222 | 353 | 246 | 39 | 458 | |
| Salvatore Corallo | 219 | 111 | 116 | 34 | 403 | |
| Angélique Vienot | 223 | 107 | 106 | 48 | 365 | |
| Hiroyuki Ito | 107 | 216 | 154 | 51 | 448 | |
| Rafael Díaz-Nieto | 168 | 228 | 122 | 32 | 405 | |
| Abdullah Zorluoğlu | 117 | 157 | 77 | 29 | 376 | |
| Shigeru Lee | 161 | 211 | 135 | 75 | 414 | |
| Byung Chul Yoo | 123 | 221 | 97 | 41 | 446 | |
| Masaomi Ikeda | 102 | 191 | 175 | 64 | 455 |
All Works
Login with ORCID to disown or claim papers
Loading papers...